Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled dose-ranging study of AD 452 in rheumatoid arthritis on methotrexate
2005-002421-31Phase 2Unknown
- Sponsor
- Arakis
- Start
- Jul 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AD 452 in rheumatoid arthritis (RA) (4 arms), sponsored by Arakis. Primary endpoint: ACR20 response at week 12. Status: unknown.
02
Drugs
AD 452
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2005-002421-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002421-31.